Conflict of Interest
Pierre, Diaccurate, Cancer
ONCOLOGY, CANCER
E.V.C. reports consulting or advisory roles with Array, AstraZeneca, Bayer, Biocartis, Bristol Myers Squibb, Celgene, Eli Lilly, Ipsen, MSD, Merck KGaA, Novartis, Pierre Fabre, Roche, Servier, Sirtex, and Taiho, and research funding to his institution from Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Ipsen, Merck, Merck KGaA, Novartis, Roche, and Servier. R.Y. reports consulting or advisory roles with Array BioPharma/Pfizer, Natera, and Mirati Therapeutics, and research funding from Pfizer, Boehringer Ingelheim, and Mirati Therapeutics. J.P.D. reports consulting or advisory roles, to the benefit of his institution, from AstraZeneca, Roche, Genentech, Bristol Myers Squibb, Diaccurate, Boehringer Ingleheim, MSD, Merch KGaA, Novartis, and Pierre Fabre, and research funding to his institution from MSD, Genentech, Transgene, BMS, and Debiopharm. J.T. reports personal financial interest in the form of a scientific consultancy role for Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, Taiho, Tessa Therapeutics, and TheraMyc. He also reports educational collaborations with Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education, and Physicians Education Resource (PER). He declares institutional financial interest in the form of financial support for clinical trials or contracted research for Amgen Inc, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Janssen-Cilag SA, MedImmune, Menarini, Merck Health KGAA, Merck Sharp & Dohme, Merus NV, Mirati, Novartis Farmacéutica SA, Pfizer, Pharma Mar, Sanofi Aventis Recherche & Développement, Servier, Taiho Pharma USA Inc, Spanish Association Against Cancer Scientific Foundation, and Cancer Research UK. L.L.S. reports consulting or advisory roles with Merck, Pfizer, AstraZeneca/Medimmune, Morphosys, Roche, Oncorus, Symphogen, Seattle Genetics, GlaxoSmithKline, Voronoi, Treadwell Therapeutics, Arvinas, Tessa, Navire, Relay, Rubius, Janpix, and Daiichi Sankyo; and stock ownership in Agios (spouse); and a leadership position in Treadwell Therapeutics (spouse). M.D. reports consulting or advisory roles with Merck KGaA, MSD, Roche, Pierre Fabre, AstraZeneca, Bayer, HalioDX, Eli Lilly, Genentech, Servier, Daiichi Sankyo, and Amgen, and research funding to his institution from Bayer, Pfizer, and Roche. S.S. reports being an advisory board member for Agenus, AstraZeneca, Bayer, BMS, CheckmAb, Daiichi-Sankyo, GSK, Guardant Health, Menarini, Merck, Novartis, Pierre-Fabre, Roche-Genentech, Seagen, and T-One Therapeutics. E.E. reports advisory roles with Amgen, Bayer, Merck Serono, MSD, Pierre Fabre, Roche, Sanofi, and Servier. S.K. discloses honoraria (self) from Merck, Amgen, Roche, Sanofi-Aventis, Servier, Pierre Fabre, and Lilly; honoraria (institution) from Merck, Amgen, Roche, and Lilly; advisory/consultancy roles with Merck, Bristol Myers Squibb, Amgen, Roche, MSD, Sanofi-Aventis, Servier, and Lilly; research grants/funding (self) from Merck, Roche, Bristol Myers Squibb, and Lilly; research grants/funding (institution) from Merck, Roche, Bristol Myers Squibb, and Lilly; and travel/accommodation expenses from Merck, Amgen, Bristol Myers Squibb, Roche, Sanofi-Aventis, Servier, and Lilly. T.Z. reports consulting or advisory roles with Novartis, Bristol Myers Squibb, MSD, Pfizer, and Eli Lilly. N.S. reports advisory/consultancy roles for AIMM Therapeutics, Boehringer Ingelheim, Ellipses Pharma, and research grants for the institute from AB Science, AbbVie, Actuate Therapeutics, Amgen, Array, AstraZeneca/MedImmune, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Cantargia, CellCentric, Cytovation, Deciphera, Genentech/Roche, GlaxoSmithKline, Incyte, Lilly, MSD, Merus, Molecular Partners, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Taiho, and Takeda (outside the submitted work). D.M. is an employee of Pfizer and is a Pfizer stockholder. M.E. was an employee of Pfizer and a Pfizer stockholder at the time of the study. Z.A.W. reports consulting/advisory roles with Daiichi, Arcus, Amgen, Ipsen, Array BioPharma, Novartis, Lilly, Merck, Merck KGaA, Pfizer, Bristol Myers Squibb, Bayer, AstraZeneca/MedImmune, and Macrogenics, and has been compensated for travel by Amgen, Lilly, Merck, and Bayer. His institution receives funding from Novartis, Plexxikon, Pfizer, Merck, and Arcus Therapeutics.